Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Candidate gene studies have reported associations between common SLC18A2 (VMAT2) polymorphisms and Schizophrenia susceptibility and related neurocognitive deficits. In a cohort of 718 patients, rs363227 in SLC18A2 was linked to increased schizophrenia risk (OR = 1.51) and impacted cognitive performance (PMID:22532702). A north Indian sample of 601 case–parent trios yielded nominal associations of SLC18A2 SNPs (rs363399, rs10082463) with schizophrenia and executive function measures, although these findings did not withstand multiple correction (PMID:23932573). A Han Chinese study of 430 patients and 470 controls found no overall association for rs363371 and rs363324, but identified a male-specific protective effect of the rs363371 AA genotype (OR = 0.56) in males (PMID:33099987).
Functional promoter analyses demonstrated that specific SLC18A2 haplotypes alter VMAT2 expression by ~20%, defining alleles that confer protection against alcoholism; however, their direct impact on schizophrenia has not been tested (PMID:15829504).
Despite biological plausibility linking VMAT2-mediated monoamine vesicular storage to schizophrenia pathophysiology, the limited number of probands, absence of segregation data, and inconsistent replication across populations support a Limited level of clinical validity for the SLC18A2–schizophrenia association. Additional well-powered genetic studies and functional assays in neural systems are required.
Key Take-home: Current evidence for SLC18A2 as a schizophrenia risk gene is limited and not yet sufficient for clinical application.
Gene–Disease AssociationLimitedMultiple small candidate gene studies with nominal associations and no segregation or replication Genetic EvidenceLimitedCandidate SNP associations in 718 probands ([PMID:22532702]) and 601 trios ([PMID:23932573]) with inconsistent replication and no segregation Functional EvidenceLimitedIn vitro promoter haplotype assays show altered VMAT2 activity ([PMID:15829504]) with no direct schizophrenia-relevant functional data |